Filing Details
- Accession Number:
- 0001209191-18-060680
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-12-03 19:00:20
- Reporting Period:
- 2018-12-03
- Accepted Time:
- 2018-12-03 19:00:20
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1604464 | Atara Biotherapeutics Inc. | ATRA | Biological Products, (No Disgnostic Substances) (2836) | 460920988 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1702457 | Joe Newell | C/O Atara Biotherapeutics, Inc. 611 Gateway Blvd., Suite 900 South San Francisco CA 94080 | Chief Tech. Operations Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-12-03 | 1,500 | $20.40 | 33,358 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-12-03 | 973 | $40.61 | 32,385 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-12-03 | 400 | $41.97 | 31,985 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-12-03 | 127 | $42.54 | 31,858 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (Right to Buy) | Disposition | 2018-12-03 | 1,500 | $0.00 | 1,500 | $20.40 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 72,500 | 2024-04-03 | No | 4 | M | Direct |
Footnotes
- Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018.
- The price in Column 4 is a weighted average sale price. The prices actually received ranged from $40.30 to $41.28. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- The price in Column 4 is a weighted average sale price. The prices actually received ranged from $41.40 to $42.38. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- The price in Column 4 is a weighted average sale price. The prices actually received ranged from $42.49 to $42.66. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- 25% of the shares shall vest one year from April 3, 2017, and the remaining shares shall vest in 36 equal monthly installment thereafter, subject to the reporting person's continuous service.
Billionaire Hedge Funds
